Tenosynovial giant cell tumor
MONDO:0002522A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse.
Also known as: fibrous histiocytoma of tendon sheath, giant cell neoplasm of Tenosynovium, giant cell neoplasm of tendon sheath, giant cell neoplasm of the Tenosynovium, giant cell tumor of Tenosynovium, giant cell tumor of tendon sheath, giant cell tumor of the Tenosynovium, giant cell tumour of the Tenosynovium
1470 clinical trials for this condition and its sub-types, 12 tagged with Tenosynovial giant cell tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Tenosynovial giant cell tumor
-
New drug could shrink rare joint tumors without surgery
Disease control OngoingThis study tests an investigational drug called emactuzumab for people with a rare joint tumor (TGCT) that can't be removed surgically. About 128 participants will receive either the drug or a placebo to see if it shrinks tumors and improves joint function. The goal is to offer a…
Phase 3 • Sponsor: SynOx Therapeutics Limited • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug shows promise for rare joint tumor
Disease control OngoingThis phase 3 trial tests the drug pexidartinib in 40 adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that causes pain and limits movement. The study focuses on people whose tumors are severe and cannot be helped by surgery. Researchers are…
Phase 3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug shows promise for rare joint tumor in early trial
Disease control OngoingThis study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…
Phase 1/2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill shows promise for rare joint tumor in Late-Stage trial
Disease control OngoingThis Phase 3 trial tests whether the drug Pimicotinib (ABSK021) can shrink tumors and improve symptoms in people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that cannot be surgically removed. About 94 adults will receive either the drug or a …
Phase 3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…
Phase 3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC